Boehringer–Celeris Therapeutics: targeted protein degraders, 202204– collab AI-based drug discovery for target of Boehringer

	Period	2022-04-04
	Partner, 1st	Boehringer Ingelheim (Group)
	Partner, 2nd	Celeris Therapeutics GmbH
	Group	Celeris Therapeutics (CelerixTx) (Group)
	Product	protein degradation drug
	Product 2	AI-based drug discovery / AI-based drug development

Celeris Therapeutics GmbH. (4/4/22). "Press Release: Celeris Therapeutics and Boehringer Ingelheim Enter Collaboration to Develop Next-generation Targeted Protein Degraders". Menlo Park, CA.

Boehringer Ingelheim leverages CelerisTx’s proprietary AI-based platform to generate novel proximity-inducing compounds to degrade pathogenic proteins

CelerisTx, a biopharmaceutical company focusing on AI-driven development of next-generation targeted protein degraders, announces a drug discovery collaboration with Boehringer Ingelheim to generate new chemical entities.

Under the terms of the agreement, CelerisTx will apply its platform to generate and synthesize molecules on a target agreed with Boehringer Ingelheim. Boehringer Ingelheim contributes the protein-of-interest and additional background information.

CelerisTx’s solution promises to streamline degrader design and discovery with its Celeris One™ platform. Their discovery engine exploits a combination of cutting-edge machine learning methods such as, active learning, a unique database of processed degrader information, novel linker generation for heterobifunctional degraders, and a currently under construction robotic wet lab facility for closed-loop drug discovery. The company’s generated protein degrader molecules are clearly differentiated from other targeted protein degradation technologies.

Christopher Trummer, CelerisTx’s co-founder, acting Chief Executive Officer and President commented:

"We are thrilled to have entered this collaboration with Boehringer Ingelheim. Our deal clearly highlights the great promise for next-generation protein degraders, and we are happy to leverage each other’s drug discovery expertise on many levels – from AI to biology and chemistry."

Jakob Hohenberger, CelerisTx’s co-founder, acting Chief Financial Officer commented:

“Boehringer Ingelheim is the kind of partner you wish to have. Open to cutting-edge innovation deeply rooted in creating much-needed medicines. We are happy that Boehringer Ingelheim has set up its R&D tents in Austria, just like CelerisTx, and we currently see a real science hub emerging with additional young companies in the field of proximity-inducing compounds and degraders.”

About CelerisTx

Founded in 2020, CelerisTx is a US-Austrian partially integrated drug discovery company focused on AI-driven development of novel degrader molecules that enable medicinal chemistry and drug design in the field of targeted protein degradation. CelerisTx develops the Celeris One platform, a closed-loop discovery engine that predicts biomolecular interactions, generates new chemical entities that meet relevant degrader success criteria, and extends this knowledge to synthesis and biochemical validation. The application of this discovery engine promises to streamline the way potent degraders are discovered while increasing productivity in upstream research and development.

CelerisTx partners with pharma and biotech companies and develops its drug pipeline in the areas of neurodegenerative diseases and oncology. The offices are located in Menlo Park, California and Graz, Austria, with laboratory operations to commence in the coming months.

Find more information on www.celeristx.com.